The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Baseline tumor genomic and gut microbiota association with clinical outcomes in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation.
 
Shiao-Pei S. Weathers
Research Funding - Exelixis; Genentech/Roche (Inst); Mundipharma (Inst)
 
Haifeng Zhu
No Relationships to Disclose
 
Mark Knafl
No Relationships to Disclose
 
Ashish Damania
No Relationships to Disclose
 
Carlos Kamiya-Matsuoka
No Relationships to Disclose
 
Rebecca A. Harrison
No Relationships to Disclose
 
Larry Lyons
Employment - Genentech
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene; Roche
Travel, Accommodations, Expenses - Genentech
 
Cindy Yun
Employment - Genentech/Roche
Stock and Other Ownership Interests - Roche
 
Walter C. Darbonne
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Patents, Royalties, Other Intellectual Property - US patent pending: Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Monica Loghin
No Relationships to Disclose
 
Marta Penas-Prado
No Relationships to Disclose
 
Nazanin Majd
Consulting or Advisory Role - Baxter (I); Celularity; Sumitomo Dainippon Pharma Co., Ltd. Consulting
 
W. K. Alfred Yung
Stock and Other Ownership Interests - De Novo Pharmaceuticals; DNATrix; Quadriga
Honoraria - Roche
Consulting or Advisory Role - Denovo Biopharma; DNAtrix; ILCT; Quadriga; Roche
Patents, Royalties, Other Intellectual Property - DNATrix
 
Barbara Jane O'Brien
Honoraria - Seagen
 
Ignacio Ivan Wistuba
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Asuragen; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Lilly; Flame Biosciences; Flame Biosciences; Genentech/Roche; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; Merck; MSD Oncology; Novartis; OncoCyte; Pfizer; Sanofi
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Lilly; Merck; MSD Oncology; Pfizer; Roche
Research Funding - 4D Molecular Therapeutics (Inst); Adaptimmune (Inst); Adaptive Biotechnologies (Inst); Akoya Biosciences (Inst); Amgen (Inst); Bayer (Inst); EMD Serono (Inst); Genentech (Inst); Guardant Health (Inst); HTG Molecular Diagnostics (Inst); Iovance Biotherapeutics (Inst); Johnson & Johnson (Inst); Karus Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Sanofi (Inst); Takeda (Inst)
 
Andrew Futreal
No Relationships to Disclose
 
Jennifer Ann Wargo
Stock and Other Ownership Interests - Micronoma
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Dava Oncology; Genentech; Gilead Sciences; GlaxoSmithKline; Illumina; Merck; Novartis; Society for Immunotherapy of Cancer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Illumina; Merck; Novartis
Speakers' Bureau - Dava Oncology; Genentech; Illumina; Novartis; PER; Precision Health Economics; Precision Health Economics
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent submitted regarding the role of the microbiome in response to immune checkpoint blockade
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dava Oncology; Genentech; GlaxoSmithKline; Illumina; Novartis
 
Nadim J. Ajami
Stock and Other Ownership Interests - Moderna Therapeutics
Research Funding - SNIPR BIOME
 
Scott Eric Woodman
Stock and Other Ownership Interests - WEAVR Health
 
John Frederick de Groot
Employment - ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; WuXi Biologics; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; Agios; Bioasis Technologies; Cure Brain Cancer Foundation; Debiopharm Group; DelMar Pharmaceuticals; Genentech/Roche; GenomiCare; GlaxoSmithKline; InSightec; Janssen; Karyopharm Therapeutics; KIYATEC; Magnolia Innovation; Merck; Monteris Medical; Mundipharma Research; Novartis; Prelude Therapeutics; resTORbio; Samus Therapeutics; Sapience Therapeutics; Tocagen; Voyager Therapeutics
Research Funding - CarThera (Inst); Haihe Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Other Relationship - VBI Vaccines